Cambridge Cognition Share Discussion Threads

[battlebus2] 14/4/2015 07:49

Sales of Cantab IPad exceed £1 million.

[hastings] 25/3/2015 17:22

May also be of interest to holders or those taking a look.

[phowdo] 12/3/2015 09:06

Happy with commercial progress and outlook.
Few headwinds for Cantab in the NHS, but I expect the US and private healthcare will more than compensate. They've now got the selling point it works in practise (15k patients in NHS) which is always a barrier in healthcare technology - no-one wants to be first mover.

[loobrush] 12/3/2015 08:47

Starting to look very good here, with profits already in first quarter, which I was not expecting.
This could really motor if their system gets widely adopted in the NHS and the US, the market is huge and this is the illness of the moment where all the money is being spent.Great.

[battlebus2] 12/3/2015 07:28

Results as expected with the co profitable in the second half and on track for maiden profits for full year 2015.

[hastings] 09/3/2015 22:19

Hi Charleyduck, glad you found it of interest and thanks for pointing out my writing the forecast numbers the wrong way round, so no problem with the nit-pick
(will now proceed to correct that point)
It could certainly prove to be a very interesting story, although as I say, for now I will await developments.

Cheers H

[charleyduck] 09/3/2015 22:04

Hi Hastings,
Thank you for the link to your private punter article. Very interesting, intriguing background and great review of the present position and possibilities for the future.

May I just nit-pick over a couple of figures in the penultimate paragraph? I think the writer may have transposed a couple of figures.

I think that FinnCap have their break through pre-tax profit for the full year 2015 as £0.3 million (not 1.7) and their EPS as 1.7p (not 0.3).

I think that puts COG on a this year’s PE ratio of about 43 ….. so I still think the article’s comment that they are fully priced for now - until we see this year’s numbers on Thursday and the forward outlook – is probably right.


But whilst the 2015 PE ratio at 43 is high (12.8m/0.3m), if the same growth were to continue for the next year the 2016 PE ratio would be down below 7 !
Now, wouldn’t that be nice!

It is certainly possible. It assumes a growth in revenue from £7.2m (FinnCap’s 2015) to £9.5m in 2016.

This is a 32% increase year on year, the same as FinnCap’ 2014 to 2015 growth.
One could reasonably assume that the costs of sales and operating costs also again increase at the same rate. This would take them to £7.45m.

This gives a Pre-Tax profit of £2.05m. As a contingency, let us take a quarter of a million pounds off this, just in case revenue falters or costs blip up a bit. So, let us say a PTP of £1.8million for 2016.

The 2016 PE would be 7 (12.8m/1.8m)

Perhaps therefore, if we get confirmation that the growth is something like FinnCap are expecting, say in the Interims which should come out in September this year, then perhaps a PE of 14 would not be untoward for a growth stock. This would imply a share price of 150p and Market Cap of £25.5million.

Anyway, that was the rough concept for me picking it for the 2015 NFSC Competition !!

[hastings] 08/3/2015 22:23

Not so detailed, but a few thoughts

[battlebus2] 06/3/2015 14:27

Thanks davidosh..

[davidosh] 06/3/2015 14:19

An incredibly good and detailed write up over on TMF....

[battlebus2] 04/3/2015 12:43

4 March 2015
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')

US office opened

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests, announces the opening of a US office in Salt Lake City to meet the growing demand from both existing and new North American customers. This is a central development for the Company and highlights the Company's strategy to target this market.

The US office will be headed by former Baxter and Myriad executive Bill Rusconi and will support the continuing use of Cantab as the leading cognitive assessments in both pharmaceutical clinical trials and academic research but also increase the global reach of the Company's emerging healthcare technology division.

The cloud-based Cantab Connect range is already used extensively in central nervous system (CNS) drug trials, where the iPad based products have gained widespread acceptance for their ability to deliver rapid, accurate and reproducible clinical measures of cognitive function across multiple sites. However, a growing awareness of the need to assess cognitive performance is contributing to the increased adoption of Cantab technology in pharmaceutical, academic and healthcare sectors.

Commenting on the announcement, Dr Nick Kerton, CEO of Cambridge Cognition said: "The establishment of a US office, with a team providing business development, customer support and cognitive science experience and expertise, is a natural move for Cambridge Cognition. Having a strong US presence will not only enable us to strengthen our leadership in the pharmaceutical clinical trials market, but also to invest in the education and conversion of customers in internationally renowned centres where academic research, clinical development and healthcare diagnostics come together."

[phowdo] 03/3/2015 09:34

Im not expecting too much from these results.
However, I do believe they will be taken over within next few years as their IP is going to become very useful.

Recent Beeb article on governments commitment to dementia research.

[battlebus2] 03/3/2015 09:07

Results Thursday 12th March...

[battlebus2] 21/1/2015 17:15

Finn cap reiterates their buy stance and £1 target today..

[phowdo] 21/1/2015 08:27

Possible one of their clients/potential clients asked them for the iPad integration. Much easier to test people by passing them an iPad than getting them to use a PC/laptop. Much simpler User Interface for the elderly too id imagine.

[battlebus2] 21/1/2015 07:43

New iPad research platform.

[battlebus2] 02/1/2015 09:07

A great start to 2015 here also :))

Bit of a rise before the next news of profitabilty perhaps.

[loobrush] 16/12/2014 18:38

phowdo-you seem to be correct,however on companies website holdings are as follows at 1 Oct.(Does not include Helium)

Major shareholders As at 01 October 2014, shareholders holding more than 3% of the share capital of Cambridge Cognition Holdings plc were:

Name No. of ordinary shares %
Euroblue Investments Limited 3,435,714 20.29%
Octopus Investments Nominees Ltd 3,048,264 18.00%
Michael Buxton 2,889,589 17.07%
Artemis Fund Managers Ltd 714,285 4.22%
AXA Investment Managers UK Ltd 714,285 4.22%
Investment Solutions (SA) 650,000 3.84%
Hargreave Hale 512,376 3.03%
- See more at:
However maybe the Helium holding is Investment solution(SA) anyone an idea about this ?

[phowdo] 16/12/2014 16:22

Its a disposal of the 650k that they acquired back in July.

[loobrush] 16/12/2014 16:12

Rns -this is a NEW investor holding as far as I can see.

[phowdo] 16/12/2014 15:34

Looks like that's the seller cleared.

[battlebus2] 15/12/2014 17:53

Brokers target £1

[loobrush] 15/12/2014 17:52

Directors buying is quite amazing as they have also been granted options only recently as well. Must be something coming up in the new year to prompt this buying. They have stated that they will be profitable next year, maybe the are going to get a rollout deal of their dementia kit with the NHS shortly.
Not many free float shares so a deal could see this motor.
Fingers crossed.

[phowdo] 15/12/2014 09:28

More director buys around the bid on Friday.
There was also a 296k transaction at that price - perhaps Nigel Wray?
Must be clearing a seller at that price anyway.